ReviewClinical reviews in allergy & immunology2013
Cytokine-based therapy in psoriasis.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- The Potential Anti-psoriatic Effects of Andrographolide: A Comparative Study to Topical Corticosteroids.Recent advances in inflammation & allergy drug discovery · 2025Article
- Psoriasis and Atherosclerosis-Skin, Joints, and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics.International journal of molecular sciences · 2021Review
- Importance of Redox Equilibrium in the Pathogenesis of Psoriasis-Impact of Antioxidant-Rich Diet.Nutrients · 2020Review
- An Injectable Cytokine Trap for Local Treatment of Autoimmune Disease.Biomaterials · 2020Article
- Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients.Diseases (Basel, Switzerland) · 2018Article
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.Frontiers in immunology · 2018Review
- Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators.ACS nano · 2017Article
- [A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.International journal of molecular medicine · 2017Article
- The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables.Dermatology and therapy · 2016Review
- Galectin-3 in autoimmunity and autoimmune diseases.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.PloS one · 2015Observational
- Autoimmunity in 2013.Clinical reviews in allergy & immunology · 2014Review
- Unique topics and issues in rheumatology and clinical immunology.Clinical reviews in allergy & immunology · 2014Article
- Targeting interleukin-22 in psoriasis.Inflammation · 2014Review
- S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.Journal of immunology research · 2014Article
- The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis.Clinical & developmental immunology · 2013Review
- Steps in the management of psoriatic arthritis: a guide for clinicians.Therapeutic advances in chronic disease · 2012Article
- Screening of Latent Tuberculous Infection (LTBI) before Starting Anti-Tumor Necrosis Factor Therapy in Patients with Psoriasis: A Primer for Clinical Dermatologist.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis and psoriatic arthritis are chronic inflammatory diseases of unknown etiology, affecting 2-3% of the world population. Initially, psoriasis was thought to be a hyper-proliferation disorder of keratinocytes only, but as time passed, the role of immune system became more evident and now both diseases are considered autoimmune disorders. In last few years, the discovery of interleukin (IL)-23/Th17 axis in pathophysiology of psoriatic diseases shifts the cytokine paradigm from Th1 to Th17 cytokines, focused mainly on IL-17 and IL-22. Therapeutic experiences strongly support the use of cytokine antagonists as an important modality in the treatment of psoriatic arthritis and plaque psoriasis. Studies examining these therapeutic agents which target different steps of the psoriatic inflammatory cascade have also shown significant efficacy. The relatively new IL-23/Th17 axis in psoriatic diseases got more importance with the success of ustekinumab, a new monoclonal antibody against IL-12 and IL-23. In IL-17 and IL-22 knock-out and transgenic mouse models, it has been found that recombinant IL-23 fails to produce epidermal hyperplasia which resembles psoriasis. Also, some success in animal models of psoriasis was found with anti IL-17A and anti IL-22. More studies are needed to validate the efficacy and safety of these cytokine antagonists in psoriatic diseases. Using a historical perspective and a chess game as an analogy, the main objective of this review is to summarize the central role of some of these cytokines in psoriasis pathophysiology and to develop a strategic approach to new therapeutic weapons within the armamentarium of psoriasis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.